Beernink Peter T, Di Carluccio Cristina, Marchetti Roberta, Cerofolini Linda, Carillo Sara, Cangiano Alessandro, Cowieson Nathan, Bones Jonathan, Molinaro Antonio, Paduano Luigi, Fragai Marco, Beernink Benjamin P, Gulati Sunita, Shaughnessy Jutamas, Rice Peter A, Ram Sanjay, Silipo Alba
Department of Pediatrics, University of California San Francisco, 5700 Martin Luther King Jr. Way, Oakland, California 94609, United States.
Department of Chemical Sciences, University of Naples Federico II, Via Cintia 4, 80126 Naples, Italy.
JACS Au. 2024 Jul 5;4(7):2617-2629. doi: 10.1021/jacsau.4c00359. eCollection 2024 Jul 22.
The spread of multidrug-resistant strains of , the etiologic agent of gonorrhea, represents a global health emergency. Therefore, the development of a safe and effective vaccine against gonorrhea is urgently needed. In previous studies, murine monoclonal antibody (mAb) 2C7 was raised against gonococcal lipooligosaccharide (LOS). mAb 2C7 elicits complement-dependent bactericidal activity against gonococci, and its glycan epitope is expressed by almost every clinical isolate. Furthermore, we identified a peptide, cyclic peptide 2 (CP2) that mimicked the 2C7 LOS epitope, elicited bactericidal antibodies in mice, and actively protected in a mouse vaginal colonization model. In this study, we performed structural analyses of mAb 2C7 and its complex with the CP2 peptide by X-ray crystallography, NMR spectroscopy, and molecular dynamics (MD) simulations. The crystal structure of Fab 2C7 bound to CP2 showed that the peptide adopted a beta-hairpin conformation and bound the Fab primarily through hydrophobic interactions. We employed NMR spectroscopy and MD simulations to map the 2C7 epitope and identify the bioactive conformation of CP2. We also used small-angle X-ray scattering (SAXS) and native mass spectrometry to obtain further information about the shape and assembly state of the complex. Collectively, our new structural information suggests strategies for humanizing mAb 2C7 as a therapeutic against gonococcal infection and for optimizing peptide CP2 as a vaccine antigen.
淋病病原体淋病奈瑟菌多重耐药菌株的传播是全球卫生紧急情况。因此,迫切需要开发一种安全有效的淋病疫苗。在先前的研究中,针对淋球菌脂寡糖(LOS)产生了鼠单克隆抗体(mAb)2C7。mAb 2C7可引发针对淋球菌的补体依赖性杀菌活性,并且其聚糖表位几乎在每个临床分离株中都有表达。此外,我们鉴定出一种模拟2C7 LOS表位的肽,环肽2(CP2),它能在小鼠体内引发杀菌抗体,并在小鼠阴道定植模型中起到主动保护作用。在本研究中,我们通过X射线晶体学、核磁共振光谱和分子动力学(MD)模拟对mAb 2C7及其与CP2肽的复合物进行了结构分析。与CP2结合的Fab 2C7的晶体结构表明,该肽呈β-发夹构象,主要通过疏水相互作用与Fab结合。我们利用核磁共振光谱和MD模拟来绘制2C7表位图谱并确定CP2的生物活性构象。我们还使用小角X射线散射(SAXS)和天然质谱来获取有关该复合物形状和组装状态的更多信息。总的来说,我们的新结构信息为将mAb 2C7人源化作为治疗淋球菌感染的药物以及优化肽CP2作为疫苗抗原提供了策略。